Publication date: October 2026 Source: Neurotherapeutics, Volume 23, Issue 6 Author(s): Lars Masanneck, Elaine Trautmann, Judith von Pavel, Ramona Hagler, Marius Vach, Patricia Kirschner, Jan Voth, Melanie Schuette, Pascal Benkert, Jens Kuhle, Jörn Kaufmann, Marie Deffner, Nicholas Schwab, Steffen Pfeuffer, Sven G. Meuth, Marc Pawlitzki
Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab. // Neurotherapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S187874792600245X?dgcid=rss_sd_all
Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab. Neurotherapeutics. https://www.sciencedirect.com/science/article/pii/S187874792600245X?dgcid=rss_sd_all
“Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab.” Neurotherapeutics.
@article{article94821,
title = {Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab},
journal = {Neurotherapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S187874792600245X?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...